X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated in phase 1 clinial trials for the treatment of mild COVID-19 symptoms.
Lead Product(s): Interferon Alfa
Therapeutic Area: Infections and Infectious Diseases Product Name: Veldona
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
The net proceeds will be used for the preparation of IND applications for Veldona (interferon alfa) human drug candidates and advancing co-development of a volatile organic compound (VOC) sensing platform, powered by AI Nose technology.
Lead Product(s): Interferon Alfa
Therapeutic Area: Hematology Product Name: Veldona
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lind Partners
Deal Size: $1.7 million Upfront Cash: Undisclosed
Deal Type: Financing January 24, 2024
Details:
Veldona (interferon alfa) binds to type I interferon receptors (IFNAR). It is being evaluated as a potential treatment for oral warts in HIV-seropositive patients.
Lead Product(s): Interferon Alfa
Therapeutic Area: Oncology Product Name: Veldona
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
Veldona is a low-dose oral interferon formulation investigated as a potential treatment for oral warts in HIV-seropositive patients. Ainos plans to pursue a pre-IND meeting with the U.S. FDA in advance of planned Phase III clinical studies for the drug candidate.
Lead Product(s): Interferon Alfa
Therapeutic Area: Infections and Infectious Diseases Product Name: Veldona
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Under the agreement, Ainos and Merdury will evaluate the feasibility of Merdury's potential investment and participation in the completion of a Phase 3 clinical trial of the Company's Veldona (interferon alfa) drug candidate for treatment of oral warts in HIV-seropositive patients.
Lead Product(s): Interferon Alfa
Therapeutic Area: Oncology Product Name: Veldona
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Merdury Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 14, 2023
Details:
Veldona, a low-dose oral interferon-alpha formulation to boost the human body’s frontline defenses against disease and infection. IFN-α is a key component of our body’s innate immune response to viral infection. Most cells in the body will produce interferon when attacked.
Lead Product(s): Interferon Alfa
Therapeutic Area: Immunology Product Name: Veldona
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
A pre-clinical animal study we conducted since March of this year validated the effectiveness of our low-dose oral Veldona (interferon) therapy to protect against COVID-19.
Lead Product(s): Interferon Alfa
Therapeutic Area: Infections and Infectious Diseases Product Name: Veldona
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
